ReviewBiomolecules2023

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease.

Shotaro Kamata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.